Insider · CIK 0001193210
Bruce C Cozadd
ceochairofficerdirector
Files at JAZZ (Jazz Pharmaceuticals plc), SLRN (ACELYRIN, Inc.). First filing Nov 5, 2024, latest Oct 5, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 13
$0 bought, $6.0M sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
JAZZ: Jazz Pharmaceuticals plc
JAZZOct 9, 2026 · close 218.42
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 28Weak | Jazz Pharmaceuticals plc | $1.4M 6,000 shares | -2% | +78% from low-11% from high | |
| 45Moderate | Jazz Pharmaceuticals plc | $1.5M 6,000 shares | -2% | - | |
| 17Weak | Jazz Pharmaceuticals plc | $772k 6,000 shares | -1% | +33% from low-10% from high | |
| 15Weak | Jazz Pharmaceuticals plc | $113k 1,000 shares | -0% | +18% from low-20% from high | |
| 15Weak | Jazz Pharmaceuticals plc | $108k 1,000 shares | -0% | +12% from low-24% from high | |
| 15Weak | Jazz Pharmaceuticals plc | $109k 1,000 shares | -0% | +11% from low-25% from high | |
| 17Weak | Jazz Pharmaceuticals plc | $176k 1,500 shares | -0% | +17% from low-19% from high | |
| 17Weak | Jazz Pharmaceuticals plc | $186k 1,500 shares | -0% | +19% from low-13% from high | |
| 44Moderate | Jazz Pharmaceuticals plc | $938k 6,500 shares | -1% | - | |
| 17Weak | Jazz Pharmaceuticals plc | $183k 1,500 shares | -0% | - | |
| 17Weak | Jazz Pharmaceuticals plc | $185k 1,500 shares | -0% | - | |
| 26Weak | Jazz Pharmaceuticals plc | $242k 2,000 shares | -0% | - | |
| 23Weak | Jazz Pharmaceuticals plc | $111k 1,000 shares | -0% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | JAZZ Jazz Pharmaceuticals plc | SOpen-market sale Ordinary Shares10b5-1 | -6,000 | $230.33 | $1.4M | 345,875 | 7 d ago |
| Aug 31, 2026 | JAZZ Jazz Pharmaceuticals plc | FTax withholding Ordinary Shares10b5-1 | -10 | $244.06 | $2,441 | 359,084 | 40 d ago |
| Aug 31, 2026 | JAZZ Jazz Pharmaceuticals plc | FTax withholding Ordinary Shares10b5-1 | -1,209 | $241.39 | $292k | 357,875 | 40 d ago |
| Sep 1, 2026 | JAZZ Jazz Pharmaceuticals plc | SOpen-market sale Ordinary Shares10b5-1 | -6,000 | $250.13 | $1.5M | 351,875 | 40 d ago |
| Sep 14, 2025 | JAZZ Jazz Pharmaceuticals plc | FTax withholding Ordinary Shares | -15,647 | $126.16 | $2.0M | 414,326 | Sep 17, 2025 |
| Sep 2, 2025 | JAZZ Jazz Pharmaceuticals plc | SOpen-market sale Ordinary Shares10b5-1 | -3,000 | $127.23 | $382k | 432,973 | Sep 4, 2025 |
| Sep 2, 2025 | JAZZ Jazz Pharmaceuticals plc | SOpen-market sale Ordinary Shares10b5-1 | -3,000 | $130.00 | $390k | 429,973 | Sep 4, 2025 |
| Aug 1, 2025 | JAZZ Jazz Pharmaceuticals plc | SOpen-market sale Ordinary Shares10b5-1 | -1,000 | $113.21 | $113k | 435,973 | Aug 5, 2025 |
| Jul 1, 2025 | JAZZ Jazz Pharmaceuticals plc | SOpen-market sale Ordinary Shares10b5-1 | -500 | $105.26 | $53k | 437,473 | Jul 3, 2025 |
| Jul 1, 2025 | JAZZ Jazz Pharmaceuticals plc | SOpen-market sale Ordinary Shares10b5-1 | -500 | $110.00 | $55k | 436,973 | Jul 3, 2025 |
| Jun 2, 2025 | JAZZ Jazz Pharmaceuticals plc | SOpen-market sale Ordinary Shares10b5-1 | -500 | $107.90 | $54k | 438,473 | Jun 4, 2025 |
| Jun 3, 2025 | JAZZ Jazz Pharmaceuticals plc | SOpen-market sale Ordinary Shares10b5-1 | -500 | $110.00 | $55k | 437,973 | Jun 4, 2025 |
| May 21, 2025 | SLRN ACELYRIN, Inc. | DDisposition to issuer Director Stock Option (right to buy)derivative | -183,434 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | SLRN ACELYRIN, Inc. | DDisposition to issuer Director Stock Option (right to buy)derivative | -23,243 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | SLRN ACELYRIN, Inc. | DDisposition to issuer Director Stock Option (right to buy)derivative | -92,158 | - | - | 0 | May 23, 2025 |
| May 1, 2025 | JAZZ Jazz Pharmaceuticals plc | SOpen-market sale Ordinary Shares10b5-1 | -1,000 | $116.35 | $116k | 439,307 | May 5, 2025 |
| May 2, 2025 | JAZZ Jazz Pharmaceuticals plc | SOpen-market sale Ordinary Shares10b5-1 | -500 | $120.00 | $60k | 438,807 | May 5, 2025 |
| Apr 1, 2025 | JAZZ Jazz Pharmaceuticals plc | SOpen-market sale Ordinary Shares10b5-1 | -1,500 | $123.75 | $186k | 440,307 | Apr 3, 2025 |
| Mar 5, 2025 | JAZZ Jazz Pharmaceuticals plc | DDisposition to issuer Ordinary Shares | -22,251 | $138.95 | $3.1M | 441,807 | Mar 7, 2025 |
| Feb 27, 2025 | JAZZ Jazz Pharmaceuticals plc | AGrant or award Ordinary Shares10b5-1 | +30,814 | $0.00 | $0 | 470,558 | Mar 3, 2025 |
| Mar 3, 2025 | JAZZ Jazz Pharmaceuticals plc | SOpen-market sale Ordinary Shares10b5-1 | -6,500 | $144.25 | $938k | 464,058 | Mar 3, 2025 |
| Feb 3, 2025 | JAZZ Jazz Pharmaceuticals plc | SOpen-market sale Ordinary Shares10b5-1 | -1,500 | $122.31 | $183k | 439,744 | Feb 5, 2025 |
| Jan 17, 2025 | JAZZ Jazz Pharmaceuticals plc | AGrant or award Ordinary Shares | +29,559 | $0.00 | $0 | 455,084 | Jan 22, 2025 |
| Jan 17, 2025 | JAZZ Jazz Pharmaceuticals plc | FTax withholding Ordinary Shares | -13,840 | $122.62 | $1.7M | 441,244 | Jan 22, 2025 |
| Jan 2, 2025 | JAZZ Jazz Pharmaceuticals plc | SOpen-market sale Ordinary Shares10b5-1 | -1,500 | $123.43 | $185k | 425,525 | Jan 6, 2025 |
| Dec 2, 2024 | JAZZ Jazz Pharmaceuticals plc | SOpen-market sale Ordinary Shares10b5-1 | -2,000 | $121.17 | $242k | 427,025 | Dec 4, 2024 |
| Nov 1, 2024 | JAZZ Jazz Pharmaceuticals plc | SOpen-market sale Ordinary Shares10b5-1 | -1,000 | $110.84 | $111k | 428,976 | Nov 5, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.